Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Journal of Hematology & Oncology

卷:15

Correction

Dajun Yang¹  Ming Lu²  Na Xu³  Xiaoli Liu³  Yanli Zhang⁴  Yongping Song⁴  Li Meng⁵  Huanling Zhu⁶  Xin Du⁷  Lichuang Men⁸  Zi Chen⁸  Hengbang Wang⁸  Qian Niu⁸  Yifan Zhai⁹  Yazhen Qin¹⁰  Qian Jiang¹⁰  Zongru Li¹⁰  Xiaojun Huang¹¹  Suning Chen¹²  Bingcheng Liu¹³  Yang Liang¹⁴  Yu Hu¹⁵  Weiming Li¹⁵ 

[1] Ascentage Pharma (Suzhou) Co., Ltd, 218 Xinghu St, Bldg B7, 7Th Floor, Suzhou Industrial Park, 215000, Suzhou, Jiangsu, China;State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, 510060, Guangzhou, Guangdong Province, China;

[2] Ascentage Pharma Group Inc, 800 King Farm Blvd Suite 300, 20850, Rockville, MD, USA;

[3] Department of Hematology, Nanfang Hospital, Southern Medical University, 1838 Guangzhou N Ave, Baiyun, 510515, Guangzhou, Guangdong Province, China;

[4] Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 450008, Zhengzhou, Henan, China;

[5] Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, Hubei, China;

[6] Department of Hematology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Wuhou District, 610000, Chengdu, Sichuan, China;

[7] Division of Hematology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, 3002 Sungang W Rd, Futian District, 518000, Shenzhen, Guangdong Province, China;

[8] Guangzhou Healthquest Pharma Co. Ltd., Room F314, GIBI, No. 3 Lanyue Road, 510663, Guangzhou, China;

[9] Guangzhou Healthquest Pharma Co. Ltd., Room F314, GIBI, No. 3 Lanyue Road, 510663, Guangzhou, China;Ascentage Pharma Group Inc, 800 King Farm Blvd Suite 300, 20850, Rockville, MD, USA;

[10] National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital, Peking University Institute of Hematology, No. 11 South Street of Xizhimen, Xicheng District, 100044, Beijing, China;

[11] National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital, Peking University Institute of Hematology, No. 11 South Street of Xizhimen, Xicheng District, 100044, Beijing, China;Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 South Street of Xizhimen, Xicheng District, 100044, Beijing, China;Peking-Tsinghua Center for Life Sciences, No. 11 South Street of Xizhimen, Xicheng District, 100044, Beijing, China;Academy for Advanced Interdisciplinary Studies, Peking University, No. 11 South Street of Xizhimen, Xicheng District, 100044, Beijing, China;

[12] National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China;

[13] State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 300020, Tianjin, China;

[14] State Key Laboratory of Oncology in South China, Department of Hematologic Oncology, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, 510060, Guangzhou, Guangdong Province, China;

[15] Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, Hubei, China;

关键词: ;   

DOI  :  10.1186/s13045-022-01369-2

来源: Springer

【 授权许可】

CC BY   
© The Author(s) 2022